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IDENTIFYING AND TRIGGERING APOPTOTIC MARKERS 
 IN HIV LATENT CD4+ T-CELLS 
JOSHUA MERAI 
ABSTRACT 
 Human Immunodeficiency Virus (HIV) is a global disease that has yet to be 
cured. Its most popular outbreak was in the 1980s.  Current treatment involves holding 
the virus in its dormant phase using Antiretroviral Therapy (ART). By keeping the virus 
dormant, patients are able to live their lives normally without worry of the disease 
progressing. Although their quality of life and length improve, they are still limited by the 
daily medications they are required to take. Mishaps in following the medical plan can 
result in the virus spreading and gaining tolerance to the medication, deeming it 
ineffective. Genuine elimination of the virus will remedy this issue and truly give patients 
a better quality and length of life. In order to accomplish this goal, current research has 
been investigating ways to target the latent population of HIV.  
 This study was aimed at understanding the role of BCL-2 in HIV latent immune 
cells, specifically CD4+ T cells. This was mainly accomplished by isolating Rhesus 
Macaque monkey peripheral blood mononuclear cells (PBMCs). Once the cells were 
isolated, they were stained with the appropriate antibodies to help in identifying specific 
subpopulations. These subpopulations were Monocytes, B cells, and T cells. BCL-2. 
OX40 and p27 levels of expression were analyzed and measured on these subsets. OX40 
and p27 were also of interest because of the similar roles they play when viruses infect 
healthy cells.  
 
 v 
 The results of this study showed high correlation between all three proteins (BCL-
2, OX40, and p27) on latent infected CD4+ T cells. These correlations were transient 
through all subpopulations of PBMCs, as well as, Simian Immunodeficiency Virus (SIV) 
infected and non-infected specimens. Although no statistical test to prove significance 
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Innate and Adaptive Immune System 
 All organisms have an intrinsic system with the sole purpose of fighting off 
infection. This system is called the immune system. In humans, specifically, there are two 
subsequent categories - the innate and the adaptive. The innate immune system is 
specialized in protecting the host from exogenous pathogens. These pathogens can come 
from many sources; for example, consumed foods, inhaled substances, or topical particles 
1. The adaptive immune system, on the other hand, is in charge of remembering any 
infection the host has come across. It uses this memory to fight off the infection, 
whenever it presents itself again. Both of these specific pathways utilize various 
components that aid in their success. A compromise of any of these components will lead 
to prolong infection and a lack of proper immunity. 
 The innate immune system is the first pathway to be triggered. A cascade of 
events occurs, and various components of this system are activated. These components 
are comprised of inflammation, phagocytosis, cytokine release, natural killer cell (NK 
cell) deployment, and in some cases, a complement system 2. In the event that these 
components do not subvert the threat, the adaptive immune system is called into action. 
Triggering of this system is set off when pathogen-associated molecular patterns 
(PAMPs), located on the surface of the pathogen, are recognized as ‘non-self’ 
molecules1. Once this recognition occurs, macrophages engulf the foreign body and 
degrade it, or they present a marker on its surface for cytotoxic T-cells to promote 
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destruction. After the pathogen is contained, memory B cells work to continually protect 
the host from future attacks.  
 
Infectious Diseases: Viral Infection (Human Impact) 
The majority of viral infections work in the same manner. When a virus enters 
into a host, its goal is spreading through replication. This replication begins as soon as the 
virus enters into a host cell and ‘hijacks’ the machinery necessary to create proteins in the 
ribosome. The cellular machinery starts to replicate the viral genome to create duplicate 
viruses and viral genetic material. In most of the viral infections, once the virus depletes 
the resources of the cell, it causes the cell to lyse, and the replicated viruses infect other, 
healthy cells in the host 3. In order to rid the body of the virus, natural defenses seek to 
raise body temperature and blood pH in order to de-coat and denature the viral protein. 
The human immune system fights off and remembers viruses very often. 
Common viral diseases that the human immune system is exposed to are the 
rhinovirus, influenza, variola, and herpes simplex virus. These viruses operate in both 
similar and different ways. Herpes virus, for example, works differently in that it can 
avoid detection by remaining dormant in a cell, a capability called called latency 3. Many 
viruses have this ability to become latent and, later on, reactivated. Today’s scientific 
discoveries have yet to determine a technique of removing the latent factor. It is 
imperative to remove that factor in order to neutralize and exterminate these types of 
viruses. Another virus that acts similarly, but with more potency, is called the Human 
Immunodeficiency Virus (HIV).  
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Human Immunodeficiency Virus (HIV) 
The human immunodeficiency virus is classified under the genus Lentivirus and 
under the family of Retroviridae. This virus is subdivided into type 1 and 2. HIV-1 has 
originated from Central American chimpanzees, whereas HIV-2, originated from West 
African sooty mangabeys 4. Simian Immunodeficiency Virus (SIV) is the nomenclature 
for non-human primates, but this virus also exists in other animals and mammals. These 
viruses function in comparable ways; for HIV, the structure is fundamentally important in 
understanding and determining a solution. 
 
HIV Structure 
As with all other viruses, HIV is not a living organism. However, it has many 
similarities to a cell. Just like any cell, HIV contains genetic material that is enveloped by 
an inner capsid. This capsid is similarly enclosed by a matrix protein and lipid membrane 
with a surface containing glycoproteins 4. All of these components, especially the genetic 
material, are integral in sustaining the life of the virus. The genetic material consists of 
two single stranded ribonucleic acid (RNA) sequences. These sequences, once inside a 
host cell (CD4+ T cells), utilize the ribosomal machinery to generate pro-viral DNA that 
is subsequently incorporated into the host’s DNA. The host cells continue producing 
antibodies against HIV, while simultaneously, losing immune cells because of infection 
and lysing. Although the original virus molecule would have disseminated by this time 





HIV is known for its role in depleting healthy CD4+ T lymphocytes, which are 
important in fighting off infection. The virus is attracted to these immune cells by means 
of surface proteins. The envelope that encapsulates the virus is protein Gp120 5. This 
protein interacts with CD4+ surface receptors, CC-chemokine receptor 5 (CCR5) or 
CXC-chemokine receptor 4 (CXCR4). This interaction starts the cascade of events 
beginning with conformational changes in the viral protein, which necessitates the fusion 
of the viral envelope to the host cellular membrane. Once fused, HIV RNA, reverse 
transcriptase, integrase, and other viral proteins are injected into the host cell. These are 
the tools, together with the cellular machinery, that are necessary for replication. Viral 
DNA is formed by reverse transcription utilizing the corresponding enzyme5. After 
formation, viral integrase enables the viral DNA to enter into the nucleus of the cell in a 
structure called the pre-integration complex (PIC) and to subsequently integrates into the 




Figure 1. HIV Life Cycle and Replication. This diagram depicts the steps of replication of the 
HIV life cycle. The steps go in chronological order from step 1 to step 6. Details are given within text 
boxes. CCR5, C-C chemokine receptor 5; CD4, cluster of differentiation 4; CXCR4, C-X-C chemokine 
receptor 4; INSTI, integrase strand transfer inhibitor; NNRTI, non-nucleoside reverse-transcriptase 
inhibitor; NRTI, nucleoside reverse-transcriptase inhibitor6. 
               
Post-integration of the viral DNA primarily entails gene expression and 
production of viral proteins. Gene transcription is initiated by a promoter upstream of 
long terminal repeats (LTR). Viral proteins Tat, Rev and Nef are translated by the host 
cell machinery. Tat increases transcription efficiency, whereas Rev exports messenger 
ribonucleic acids (mRNAs), including Env, Vif, Vpr, Vpu, Gag, and Pol 4. After 
completion of these steps, budding and viral morphogenesis begins. Viral morphogenesis 
is the process of the virus gaining its shape and organization of inner materials. Once 
budding is finished, the virus becomes completely infectious after the Gag polyprotein is 
cleaved by the viral protease. For the newly replicated viruses to then exit the host cell 
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and infect other cells, the original host CD4 lymphocyte must be lysed 5. The induced 
cellular membrane destruction is by means of apoptosis.  
 
HIV Tropism 
Viral tropism is defined as the tissue or cells that support the growth and 
development of a certain virus. HIV has developed its tropism primarily on CD4 T 
lymphocyte cells and macrophages. HIV is attracted to these two cells because of their 
expression of cluster differentiation 4 (CD4) receptors on their surface membranes. 
Because HIV is also attracted to coreceptors, CCR5 and CXCR4, these proteins are 
deemed tropic, as well 7. After transmission of the virus to the target cells, the acute 
phase of the infection begins.  
The acute phase is the first 2 to 4 weeks after the initial infection. This phase is 
characterized by a large production of HIV replicates and immune response. During this 
time, CD4+ T cells are being reduced and the virus spreads to the lymphatic organs. 
CD8+ T cells are actively trying to fight off the virus. In the next 4 to 6 weeks, the 
immune system is able to reduce the viral infection, however, the virus retreats to its 
chronic, latency phase 7. This latency phase occurs when some HIV infected immune 
cells no longer replicate new viruses – dormancy. With some of the virus lying dormant, 
CD4+ cells make a small recovery. Unfortunately, however, the viruses that are not latent 
continue to disrupt the immune system and deplete healthy CD4+ T cells. If left 
untreated, the host will be left exhausted of healthy immune cells and system. Once the 
amount of CD4+ cells fall below 50-100 cells per µl, acquired immunodeficiency 
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syndrome (AIDS) is taking place 8. At this point, the immune system is completely 
compromised and cannot fight off any infection or pathogen. Minor illnesses, like the 
common cold, are potent enough to be fatal to the host. To avoid this fatal phase, patients 
are advised to begin antiretroviral therapy (ART).  
 
Antiretroviral Therapy 
Antiretroviral therapy (ART) is most commonly successful in rehabilitating 
patients with HIV. ART can be used to target any of the five distinct steps in HIV 
infection. These steps are viral entry, replication, reverse transcription, integrase and 
protease 9. Many healthcare providers prescribe multiple therapies to manage the virus on 
varied steps. This type of therapy can be known as either combination antiretroviral 
therapy (cART) or highly active antiretroviral therapy (HAART). Although these 
therapies are successful in suppressing the virus, the latent reservoirs decay too slowly to 
be fully eradicated within a patient’s lifetime10. Unfortunately, many patients cannot 
afford the lifetime expense of the daily ART medication. Interruption of the drug therapy 
results in reactivation of latent HIV reservoirs in CD4+ T cells, leading to increased viral 
replication and immune cell death. Abundant viral load can be accomplished within just 
two weeks post-cessation 9. In this situation, the virus can mutate against the medication. 
Once the virus mutates, the same drug therapy could no longer be used. Danger occurs 
when the patient transmits the disease to other individuals with a mutant, almost 
untreatable strain of HIV11 12. Thus, it is imperative to continue on a daily regimen of 
ART in order to suppress the virus and avoid mutations. For full eradication of the virus, 
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especially from latent reservoirs, further scientific findings will need to be explored.  
 
HIV Reservoir 
HIV has the ability to establish long-term infection and latency in various cells. 
CD4+ T cells are the most common type of cell; however, monocyte and macrophage 
cells are also of interest for HIV dormancy13–15. According to the SIV macaque model, 
the HIV reservoir of infected cells can be established as early as 3 days, post-infection16. 
After HIV DNA integration occurs in the host chromatin, the virus is capable of 
replicating infinitely, as long as the cell stays alive. ART is a medical treatment that 
keeps the infection from spreading, but the virus and its genome are still integrated in the 
host DNA – a major caveat in this specific therapy. Although this therapy is known for 
inhibiting viral replication, residual instances still occur at very low levels in a small 
percentage of patient samples17,18. These residual instances take place at lymph nodes 
where penetration by antiretrovirals is limited19. Due to this flaw, reactivation of the viral 
infection tends to begin at lymph nodes when patients interrupt or discontinue the ART 
treatment. Current estimates suggest it would take several decades for a latent reservoir to 
be eliminated naturally, without the aid of exogenous means, given that the host inhibits 
new viral replication by means of ART20–23.  
The HIV Reservoir is difficult to eradicate because the cells that harbors it are 
able to pass under the radar of healthy immune cells. With this ability, the HIV reservoir 
is able to stay undetected until it becomes reactivated. Current research uses an approach 
of eradicating this reservoir in order to cure the disease. Two very prominent approaches 
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are named the ‘Shock and Kill’ and ‘Block and Lock’ methods24,25. The ‘shock and kill’ 
method (Figure 2) is the process of intentionally reactivating latent reservoir and then 
utilizing the healthy immune cells to neutralize the virus26–28. Drugs that initialize the 
‘shock’ are typically classified as Latency Reversal Agents (LRAs). The logic behind the 
method is that cells will begin to produce viral antigens. With viral antigens being 
produced, the potential of the former reservoir to be recognized and terminated is much 
greater – completing the “kill” step. On the other hand, the ‘Block and Lock’ method 
operates somewhat differently. This method uses kinase inhibitors with the purpose of 
keeping latent cells in their dormant stage. Clinically, these inhibitors would be paired 
with ART. The ART would drive the virus into its latent stage, and the kinase inhibitors 
would keep it there.  
Figure 2. ‘Shock and Kill’ method on CD4+ T cells. Integration of silenced HIV genomes into 
the host genome of long-lived CD4+ memory cells (latency) results in lifelong infection. Most attempts to 
cure HIV infection involve efforts to reverse latency, resulting in the production of viral proteins and the 
eventual host-mediated clearance of the virus-producing cell (‘shock and kill’). ART, antiretroviral therapy; 
CTLA4, cytotoxic T lymphocyte antigen 4; HDAC, histone deacetylase; PD1, programmed cell death 




Unfortunately, however, scientific research has yet to find a solution to 
completely eradicating the virus. A possible resolution will entail a strategy that reduces 
the amount of latent virus under ART, as well as, prevents other cells from being 
infected. Any medication that evolves and becomes useful against the HIV infection, and 
its latency, will include the proper strategies and safety limitations. Currently, epigenetic 
modifying drugs, typically used in oncology, are being investigated in reversing HIV 
latency. In addition, drugs that promote apoptosis are being evaluated with respect to 
HIV-infected cells.  
 
Apoptotic Markers 
Apoptosis is programmed cell death – a process that eliminates cells that are 
damaged, exposed to a stress, or no longer required. Signals can trigger an apoptotic 
event through two main pathways: extrinsic or intrinsic30. Apoptotic extrinsic events 
occur when death receptors, such as, tumor necrosis factor (TNF) – related apoptosis-
inducing ligand (TRAIL) receptor (TRAILR) and FAS bind to their respective ligands. 
Through dimerization by FAS, these receptors then activate caspase-8 or caspase-10, 
which are able to cleave and subsequently activate caspase-3 and caspase-7 leading to 
apoptosis of the cell. On the other hand, the intrinsic pathway requires mitochondrial 
outer membrane permeabilization (MOMP). BCL-2 homology domain 3 (BH3) is 
engaged by cell stressors that can then lead to BAX and BAK activity and permeability. 
Anti-apoptotic protein, BCL-2 and its family of proteins, are known counteract this 
specific portion of cellular apoptosis31. After MOMP, cytochrome c and mitochondria-
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derived activator of caspases (SMAC) are released into the cytosol. Cytochrome c 
triggers azotosome assembly by interacting with apoptotic protease activating factor 1 
(APAF1). This assembly activates caspases-9 which then activates the final apoptotic 
triggers, caspase-3 and caspase-7. Release of SMAC from the mitochondria helps aid 
apoptosis by blocking the caspase inhibitor, X-linked inhibitor of apoptosis protein 
(XIAP). Crosstalk between the intrinsic and extrinsic pathways is facilitated by caspase-8 





Figure 3. Cellular Apoptosis. This figure shows the cellular components involved in the cascade 
of apoptosis by extrinsic and intrinsic pathways. Key triggers are of the caspase protein family. Red arrows 








HIV Control on Lymphocytic Apoptosis 
The potency and latency of HIV in the immune system is primarily due to 
controlling cellular apoptosis in CD4 T lymphocyte cells. Many of its viral proteins 
contribute in various ways to prevent the cellular death while lying dormant (Figure 3, 
Table 1). An important consideration is the in vivo and in vitro concentrations of the 
protein. In the former case, the concentrations of proteins in HIV infection are usually 
unknown. In the latter case, the overexpression of one of the proteins or any treatment 
with a high concentration of one protein may skew any concentration measured, and data 
would not be reflective of in vivo studies.  
 
Table 1. HIV-Encoded Proteins and Their Reported Pro- and Anti-apoptotic Impact35: Proteins 
encoding HIV have pro- or anti-apoptotic reactions. The mechanisms they utilize vary and are listed 
below, alongside them.    
Protein Pro- or antiapoptotic Reported mechanisms 
Gp120 Proapoptotic Molecular mimicry with Fas 
  Upregulation of Fas, FasL, and TNFα expression 
  G2 cell cycle arrest 
  Generation of reactive oxygen species 
  Downregulation of Bcl-2 expression 
  Phosphorylation of mTOR and p53 
  Upregulation of PUMA expression 
  Upregulation of TRAIL-R1 and -R2 
  Induction of syncytia formation 
  Activation of p38 
   
Tat Proapoptotic Upregulation of FasL expression 
  Upregulation of Bax expression 
  Upregulation of caspase 8 expression 
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  Microtubule alteration 
  Oxidative stress 
  Upregulation of RCAS-1 expression 
   
 Antiapoptotic Decreased susceptibility to TNFα and Fas 
  Upregulation of Bcl-2 expression 
  Decreased susceptibility to TRAIL 
  Downregulation of caspase 10 expression 
  Upregulation of c-FLIP expression 
   
Vpu Proapoptotic Increased susceptibility to Fas 
  Inhibition of NF-κB 
   
Nef Proapoptotic Upregulation of Fas and FasL expression 
  Downregulation of Bcl-2 and Bcl-XL expression 
  Lysosomal permeabilization and Cathepsin-D release 
  Upregulation of PD-1 
   
 Anti-apoptotic Inhibition of ASK-1 
  Inhibition of Bad 
  Inhibition of p53 
   
   
Vpr Pro-apoptotic Binding to ANT/VDAC leading to mitochondrial depolarization 
  Binding to Bax leading to mitochondrial depolarization 
 Anti-apoptotic Suppression of NF-κB proinflammatory cytokine production 
  Upregulation of Bcl-2 and downregulation of Bax expression 
   
Protease Pro-Apoptotic Cleavage of Bcl-2 





The HIV-encoded protein Gp120 is utilized in order to enable fusion of the virus 
to the host cell. In addition, it also prevents defensive apoptosis by binding to the 
coreceptor CXCR4. Through this binding, Gp120 is known to upregulate Fas, FasL, 
TNFα and to reduce expression of BCL-2. The following viral proteins also affect the 
infected cell in a very similar manner: Tat, Vpu, Nef, and Vpr. Their specific effects on 
the cell and regulation are shown in Figure 3. The downregulation of BCL-2 is an 
important defense factor in inducing cellular apoptosis36,37. The HIV virus has the ability 
to accomplish control of apoptotic cellular death in multiple areas, making it a very 
potent virus.  
          Under normal conditions, a cell experiencing ‘stress’ on its system activates 
the intrinsic pathways to insure the health of the host. During these conditions, the 
mitochondrial pathway, via BAX or BAK of the Bcl-2 family, is activated in order to 
induce cellular apoptosis. Unfortunately, the previously mentioned viral proteins, inhibit 
this pathway and prevent the host defense mechanism. These proteins specifically 
activate the phosphoinositide 3-kinase (PI3K) pathway, promoting cell survival and 
inhibiting apoptosis. This pathway is detailed below in Figure 4. After PI3K is activated, 
Akt protein is activated, which in turn inhibits proper BCL-2 function. Viral protein Nef 
is particularly known for increasing and upregulating the PI3K pathway to further 
prolong the inhibition of the BCL-2 defense process and HIV latency 29. Thus, through 




To bypass the viral actions on the cellular system, research has started to develop 
ways to aid in reactivating natural apoptotic mechanisms (Table 2). Inhibitors of 
apoptosis regulatory proteins, like the anti-apoptotic BCL-2 family of proteins, can 
trigger cell death and are under clinical development to target malignancies. Pro-
apoptotic compounds have been created in cancer research and have promising effects in 
clearing BCL-2 antagonists in regard to HIV CD4+ latent T cells. In cancer, there is an 
overexpression of BCL-2 anti-apoptotic proteins. This prevents the cancer cells from 
undergoing apoptosis. Similarly, in HIV CD4+ latent T cells, anti-apoptosis is the main 
issue. Compounds Ventoclax and Navitoclax (not listed in table 2) have been developed 
to mimic the binding domain of the BCL-2 family. Because of this ability, the BCl-2 
proteins are then available to undergo their apoptotic mechanisms 38. Although 
Venetoclax seems promising, Navitoclax comes with its issues. The latter drug appears to 
have increased toxicity and its dose-limiting necessity makes this an unfavorable drug of 
choice. Ventoclax, however, continues to be tested before further trials are pursued. 
Recent results have shown that the triple combination of strong LRAs, HIV-specific T 




Table 2. Cancer Therapies Investigated in HIV - Focus on Apoptotic Promoting Compounds31: This 





   







phase in oncology 
Proposed effect in HIV infection 
Bcl-2 antagonists Venetoclax Licensed (CLL), Phase I-III 
Inhibits anti-apoptotic BCL-2, 
sensitizing cells to apoptosis. When 
combined with LRA reactivation, 
leads to preferential apoptosis of 
HIV infected cells 
RIG-I inducers Acitretin Licensed (psoriasis only) 
Reactivates HIV transcription and 
activates RIG-I induced apoptosis, 
leading to selective apoptosis of 
HIV infected cells 
PI3k/Akt inhibitors Perifosine, arctigenin Phase I/II 
Blocks PI3K/Akt pathway 
signaling, sensitizing HIV-infected 






Inhibits inhibitor of apoptosis 
proteins (IAPs), sensitizing HIV 
infected cells for apoptosis, induces 
viral replication 
Tyrosine kinase 
inhibitors Ibrutinib Licensed 
Impairs Bruton’s tyrosine kinase on 
the surface of HIV-infected cells, 
inducing selective depletion of 
HIV-infected cells 
 
 In addition to directly blocking BCL-2 functionality, the search of upstream 
regulators led to the therapeutic exploration of OX40. Tumor necrosis factor receptor 
superfamily member 4 (OX40, CD134) and OX40 ligand (OX40L, CD134L, CD252) are 
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expressed on activated natural killer (NK) cells, dendritic cells (DCs), B cells, activated T 
cells, and Foxp3+ regulatory T cells40,41. 
 OX40/OX40L engagement modulates various biological features of lymphocytes 
(Figure 4). Interaction of OX40 with OX40L triggers a set of robust signals on T cells 
that promotes and upregulates the antiapoptotic protein on T cells. This interaction 
enhances T cell survival, cytokine production, and induction of the CD4 memory T cell 
expansion. On NK cells, OX40/OX40L binding promotes NK cell activation, cytokine 
production and cytotoxicity, as well as, enhanced targeted cell lysis. In addition, co-
stimulation in B cells, contribution to CD4 cell generation, survival and T helper 2 (Th2) 




Figure 4. OX40 Signaling. After OX40 binding with its ligand, OX40L, OX40 recruits TRAF2,TRAF3, 
TRAF5 and PI3K by an unknown mechanism. Signals are then transmitted to the nucleus through IKKα/β/γ 
and Rel A/B, thereby regulating related genes, such as up-regulation of BCL-2, BCL-XL and surviving and 
down-regulation of Foxp3 and CTLA443. 
 
 An abundance of research has been conducted in cancer immunotherapy on this 
same OX40/OX40L relationship (Table 3). Inhibition of the OX40-OX40L relationship 
showed a regression of the known inflammatory fibrosis that is usually promoted through 
this association. This relationship has also been linked to inflammatory myopathies in 
muscle and Crohn’s disease (CD). Inhibition of this pathway by means of anti-OX40 
agonists could be beneficial with its known anti-tumor effects tested in ovarian cancer, 
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breast cancer, and colorectal cancer. These effects were possible by controlling T cell-
mediated inflammation43.  
Recently, the anti-apoptotic protein surviving, also called the baculoviral inhibitor 
of apoptosis repeat-containing 5 (BIRC5), and its upstream regulator OX40 were found 
to promote survival of HIV-1- infected reservoir CD4+ T cells, specifically during clonal 
proliferation. These findings point to clinical strategies that may reduce persisting viral 
reservoirs44. 
 Apoptotic markers BCL-2 and OX40 are key in cellular survival. Combining 
these inducers of apoptosis with LRAs may potentially lead to selective death of latently 
infected cells, given the apoptotic pathway is triggered by HIV RNA or proteins. The 
marker, OX40, is on the surface of immune cells and binds to antigen-presenting cells. 
The interaction causes a cascade in which BCL-2 can be upregulated, resulting in either 
suppression or promotion of apoptosis. In the event of HIV, fusion of the virus to the 
CD4 cell by Gp120 upregulates BCL-2. This helps to ensure the survival of the virus 
because under normal circumstances, a cell that is compromised undergoes apoptosis to 
prevent the spread of the viral pathogen. Compromised immune cells are no longer able 
to control their own apoptosis. This is key in the understanding of how HIV is able to 
stay dormant in these cells for prolonged periods of time. For cells to rid themselves of 
the virus, apoptosis needs to occur potentially through BCL-2 proteins. Thus, further 
research requires the study of possible OX40 and/or BCL-2 reactivation. This work will 
include better targeting of apoptosis by improving HIV reservoir cell depletion while 







Table 3.  Clinical Trials with Anti-OX40: List of studies and investigative objectives regarding OX40 and its antagonist. Useful in understanding the 









 Human Immunodeficiency Virus (HIV) is an infection that dramatically affects 
patients’ lifespan and quality of life. In 2018, the virus was estimated to have infected 
nearly 40 million people since its significant global increase in the 1980s. Current 
treatment involves Antiretroviral Therapy (ART) that keeps the virus latent in immune 
cells. Current research targets this latency, but has been unsuccessful in ridding the virus 
from the body. The aim of this study was to investigate the role that the anti-apoptotic 
protein, BCL-2, plays in HIV latent, CD4+ T immune cells. Successful investigation may 







Isolation of Mononuclear Cells (PBMC) Using Ficoll-Hypaque 
Peripheral blood mononuclear cells (PBMC) were isolated from whole blood 
samples (Rhesus monkeys and human) utilizing gradient centrifugation. About 5-6 mL of 
blood or diluted buffy coat were placed over 4mL of cold Ficoll-Hypaque. They were 
centrifuged at 3000 rpm at 20°C for 20 minutes. After a gradient formed, a cloudy layer 
was visible which corresponded to the purified mononuclear cells. The layer was 
collected and washed using a phosphate-buffered saline (PBS)/2% fetal bovine serum 
(FBS) wash buffer. The sample was centrifuged at 1500 rpm for 5 minutes. The 
mononuclear cells pellet was resuspended in 3-5 ml of ammonium-chloride-potassium 
(ACK) lysing buffer (Life-technologies, Carlsbad, CA) for 3-5 min and subsequently 
treated with washing buffer. This was centrifuged at 1200rpm for 5 min and then 
resuspended in 5-10 mL of R10 RPMI (Roswell Park Memorial Institute) 10%FBS 
supplemented with penicillin and streptomycin for further quantification.  
 
PBMC Cryopreservation  
 After the mononuclear cells were counted, they were centrifuged at 1500rpm for 
an additional 5 minutes. The cells were then resuspended in an amount of cold freezing 
medium (90% FBS/10% dimethyl sulfoxide [DMSO]) calculated for the desired cell 
density. Aliquots of PMBC (1-2 x 107 cells/mL) were transferred into cryovials, and 
placed into a cryogenic tank of liquid nitrogen for long-term storage. 
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PBMC Thawing and Stimulation 
Prior to stimulation of the frozen PBMCs, each sample was thawed initially in a 
37°C water bath until a pea-sized pellet remained. The sample was then transferred to a 
15-mL tube containing 10mL of warm (37°C) R10+ media and 2µl Benzonase (#71205-3 
MilliporeSigma, Burlington, MA). The thawed pellet-media mixture was then centrifuged 
at 1300 rpm for 5 minutes at room temperature. Lastly, the pellet was resuspended in 
R10+ media (without Benzonase).   
For stimulation, approximately 1 x 106 cells per cm3 were placed in a 96-well 
plate with a final volume of 0.32 cm3 (200µl). The cells were then resuspended in 190µl 
R10+ media containing 10µg/ml (2X) solution of Concanavalin-A. The plate was then 
transferred to a humidified incubator set to 37°C and 5% CO2. Afterward, cell counting 
was performed using the Guava instrument. 
 
Guava Cleaning and Counting  
 The Guava instrument was used for all cell counting in this study. Cleaning of the 
instrument was required before any runs could be completed. A waste collection bottle 
was filled with 5mL of bleach. The cleaning program was selected from the “Essential 
tools” drop-down menu, followed by “Start Cleaning.” The appropriate tubes were placed 
in the correct locations according to program specifications: Blue = water, Yellow = 
empty, Purple = instrument cleaning fluid (ICF) + 10% bleach. Position 9 was selected 
for the flow cell to rest in Milliport deionized water (DI) (MilliporeSigma). An uncapped 
v-bottom tube with DI water was placed in this position. After cleaning was complete 
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(estimated 13 minutes), cell counting was able to proceed.  
 Before counting with the instrument, a 1:10 dilution was prepared for a 96-well 
plate by mixing 20 µL of the isolated PBMCs with 180 µL of Guava ViaCount Dye. A 
worklist was created on the program: Worklist Editor -> ViaCount -> Highlight tubes + 
Acquire these samples. The dilution factor was entered in the Assay-Specific Parameters 
section, along with the volume of the resuspension. Both capillaries and mixers were 
selected to be washed, the sample was mixed for 5 seconds at high revolutions per minute 
(rpm), and then Easyfit was selected. The worklist was saved, and ViaCount was started 
once the 96-well plate was loaded onto the tray. After counting, the data was transferred 
to GuavaExcel (Version 3.1) for the Guavasoft program to generate a calculated excel 
file. At the end of counting, a cleaning protocol was once again implemented in 
preparation for future use. The samples were then transported to the cytometry lab for 
further data collection. 
 
Antibody Staining 
Following the same thawing protocol, the PMBC cells were thawed prior to 
staining. They were washed using wash buffer and centrifuged at 1300rpm for 5 minutes. 
With warm R10 media, they were resuspended and taken to the Guava instrument for 
counting. Staining began with 500 µl of Live/Dead Fixable aqua for 15 minutes at room 
temperature. After this step, the cells were washed with wash buffer was added and 
allowed to rest for an additional 5 minutes. FcBlock was then added to the cells at 5 µL 
per 50 µL for 5 minutes, after which the cells were stained with surface antibody (1 
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test/5M) for 15 more minutes. Wash buffer was added to the cells, and the system was 
allowed to rest for 5 minutes. The sample was resuspended in a prepared 250-500 µL of 
Cytofix/Cytoperm while pulse vortexing and subsequently incubated for 40 minutes at 
4°c. A new Perm/Wash buffer at (1X) was made with double-distilled water. The cells 
were washed twice with approximately 3 ml of the Perm/Wash solution (1X) and 
centrifuged at 1600 rpm. Following this step, 50 µL of p-27 antibody solution (2X) was 
added, along with the appropriate CD3/CD69 antibody panel and BCL-2 antibody. The 
solution was mixed and incubated for another 40 minutes at room temperature with no 
light. Afterward, 200 µL of Perm/Wash solution (1X) was added, and the sample was 
centrifuged at 1800rpm for 5 mins utilizing the plate centrifuge. The wash was repeated 
with 250 µl of the Perm/Wash solution (1X), and the sample was then fixed with 200 µL 
of 1% paraformaldehyde/PBS (1X). Lastly, the samples were run through the flow 
cytometer for analysis.  
 
Flow Cytometry: FlowJo Analytics 
 Software for flow cytometry was utilized to calculate CD4 and CD8 T cells. The 
FlowJo program (Version 9.9+; Becton, Dickinson and Company, Ashland, OR) was 
used on a Macintosh Operating Systems. In the program, the BioData was organized into 
a sample group, and each sample had the following gating scheme: Forward Scatter Area 
(FSC-A) vs Side Scatter Area (SSC-A) (Lymphocytes), FSC-A vs Forward Scatter 
Height (FSC-H) (Single cells – to avoid doublets), CD3 vs FSC-H (T cells), CD4 vs 
CD8. The workspace was saved after statistics were added to each sample. Tables and 
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frequency calculations were then generated using “Table editor” for the sample pairs 
expressed previously. Next, complete blood count (CBC) data was downloaded to 
calculate the number of CD4 and CD8 cells. Excel programming (Microsoft Corporation, 
Redmond, WA) was utilized to calculate the cell numbers. The number of CD4 T cells 
was calculated by multiplying ‘CD4 Frequency of Lymphocyte’ by ‘Number of Total 
Lymphocytes” and then multiplying by 10. The same formula was applied for CD8 T 
cells. Finally, the CD4/CD8 ratio was calculated by dividing “CD4 frequency of 






BCL-2 Expression Modulated Upon SIV Infection 
 
 The rhesus macaques utilized for this study (IDs 2642, 2646 and 2672) were 
infected using a repeated low-dose intrarectal challenge with SIVmac251. They were 
placed on ART regimen and subsequently suspended in order to evaluate disease 
progression. At the time of sampling, infected monkeys underwent dissimilar viremia 
ranges based on viral load quantification, as shown in Table 4. A multicolor flow 
cytometry staining protocol was used to analyze the PBMCs of the rhesus macaques. This 
technique allowed for assessment of BCL-2 expression and identification of specific 
subpopulations. Cells were known to be alive because of live/dead staining. As shown in 
Figure 5, subpopulations Monocytes, B Cells, and T Cells were identified from PBMCs 
using a 14-antibody panel. This identification was made possible by using antibody 
markers appropriate to each subpopulation (CD14: Monocytes, CD20: B Cells, CD3: T 
Cells).  
 
Table 4. Viral Load Detected on Blood Plasma in SIV Infected Rhesus Macaques: This table shows the 
measured amount of SIV RNA detected in each monkey sample, specifically from their plasma. 
 
Monkey ID Log SIV RNA (copies/mL) 
rh2642 2 x 104 













Figure 5. Sequential Gating Identifying Subsets of Peripheral Blood Mononuclear Cells (PBMCs) 
and BCL-2 Expression. This figure represents flow cytometry data and its gating strategy for purified 
Rhesus Macaque monkey PBMCs. The samples were treated with specific antibody markers and analyzed 
via Flow Cytometry assays to identify the following: (A) Monocytes (CD14+), (B) B cells (CD20+), and 
(C) T Cells (CD3+, CD4+, CD8+). Gating sequence and direction are shown by arrows, and each dot on 
the graph represents an individual cell. Doublet exclusion was performed on live cells (not shown). 
Monocytes were identified by CD14+ expression, and subsequently CD3+ and CD19+ cells were gated. B 
Cells and the two subsets of CD3+ T Cells were also identified utilizing their CD markers. BCL-2 
expression was assessed on each of these subpopulations. Fluorescence Minus One (FMO) staining defined 
the gate limits (not shown).  
 
 The percentage level of BCL-2 expression in both SIV infected and naïve samples 
is shown in Table 5. It was critical to note differences between the level of expression in 
the naïve and infected samples. Both monocyte and B cell populations increased the 
expression of BCL-2, significantly.  
 
Table 5. BCL-2 Percent Expression on Rhesus Macaque PBMCs: This table shows the percent of BCL-
















T631 2.31 60.6 84 72.6 71.4 95.5 76.5 68.1 71.9 96.6 76.5 
2642 6.41 89.4 81.6 77.7 80 92 56.7 49.1 63.4 41.3 78.3 
2646 2.4 92.2 70.5 71.4 65.7 78.1 26.7 16.7 28.1 27.1 53.8 
2672 10.1 89.2 82.2 74.3 85.2 90.5 62.7 55.1 65.7 59.3 78.1 
 
 
In contrast, T cells showed a decreased expression level of BCL-2 in samples 
derived from SIV-infected monkeys compared with the non-infected monkey. In Figure 
6A, CD4+ T cells showed a discrete BCL-2 expression downregulation, and in Figure 6B, 
CD8+ T cells showed a significant decrease in BCL-2 expression. For the infected 
specimen 2646, BCL-2 expression on CD8+ T Cells was considerably lower than any of 
the other samples. In contrast, specimen 2672 (with no detectable levels on viral RNA in 
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plasma), indicated that BCL-2 expression on CD8+T cells was similar to that observed on 
naïve specimen T631. BCL-2 expression inversely correlated with the viral load detected 





Figure 6. Expression of BCL-2 on T cells of SIV infected animals: This figure shows the BCL-2 
expression specifically on CD4+ T Cells (RED) and CD8+ T Cells (GREEN) of Rhesus Macaque Patients.  
 
 
To confirm these results, tests were carried out with samples derived from two 
additionally infected animals (IDs 288-10 and 177-10). The animals were equally infected 
using a repeated low-dose intrarectal challenge with SIVmac251, they were placed on ART 
regimen, and subsequently suspended in order to evaluate disease progression. While 
monkey 288-10 developed a high viremia (5X107 Log SIV RNA copies/mL) after ART 
cessation, monkey 177-10 was able to contain the infection. Because it was not possible to 
detect any viral presence on plasma blood, monkey 288-10 was defined as a non-controller, 




cells derived from non-controller monkey (ID 288-10) showed a significant decrease in 
comparison with the controller monkey (ID 177-10). In accordance with previous results, 
SIV-infected monkeys that showed progression of the disease after ART cessation (based 
on higher levels of virus on blood plasma) also had a significantly lower expression of 
BCL-2 on CD8+T cells.  
 
 
Figure 7. Expression of BCL-2 in CD8+T cells of SIV infected animals: This figure shows the level of 
BCL-2 expression on CD8+ T Cells in relation to a control. 
 
The acute level of BCL-2 expression could be indicative of progressed HIV 
infection. For parallel analysis with the same flow cytometry protocol, human PBMCs 
were also analyzed. The generated data produced were comparable with the BCL-2 
expression levels observed in Rhesus monkeys (data not shown). The results are indicative 
of BCL-2 expression on the previously mentioned subpopulations of PBMCs derived from 
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Rhesus monkeys. They suggest that BCL-2 expression is modulated by the SIV-infected 
cells, and its expression may have an impact on infection outcome.  
 
 
OX40 Expression Modulated Upon SIV infection. 
 Similar to the experimental approach used for BCL-2 analysis, OX40 expression 
was identified by multicolor flow cytometry protocol on Rhesus monkey PBMCs. Samples 
2646 and 2672 were used because of their dissimilar viral load quantification that was assed 
at the time of the experiment (Table 4). Because OX40 expression was low under normal 
conditions, and in order to assess the ability of cells to express OX40, PBMCs were 
stimulated using a phorbol myristate acetate (PMA)/Ionomycin treatment.  Subpopulations 
were recognized for the assessment of its expression (Monocytes, B Cells, and T cells) in 
non-stimulated and stimulated PBMCs as depicted in Figure 8. These subpopulations were 
identified using antibody markers CD14, CD20 and CD3. OX40 expression was analyzed 
within each of these subpopulations and percentages are listed in Table 6. The table 
represents the percentage of OX40 expression within each subpopulation shown in Figure 
8. A larger expression from a graph in Figure 8 correlates to a larger percentage in the 
table under the same subpopulation. The main takeaway from these two data depictions is 
the highlight of subpopulations, as well as, the dissimilarity between these two infected 
samples in regard to OX40 expression.  
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Figure 8. Sequential Gating Identifying Specific Subsets of Peripheral Blood Mononuclear Cells 
(PBMCs) and OX40 Expression. This figure represents flow cytometry data that illustrate the gating flow 
and strategy used to analyze purified PBMCs from Rhesus Macaque monkeys. (A) Illustrates the flow 
analysis of OX40 expression of sample 2642 while (B) is of sample 2672. The samples were treated with 
specific antibody markers used to recognize the specific subsets: Monocytes (CD14+), B cells (CD20+), and 
T Cells (CD3+, CD4+, CD8+). Gating sequence and direction is shown via arrows and each dot on the graph 
represents an individual cell. Doublet exclusion was performed on live cells (not shown). Monocytes were 
identified via CD14+ expression and subsequently CD3+ and CD19+ cells were gated. B Cells and the two 
subsets of CD3+ T Cells were also identified utilizing their CD markers. OX40 expression was assessed on 




Table 6. OX40 Percent Expression on Rhesus Macaque PBMCs: This tables shows the percent (%) 
expression of OX40 on each subsection of Rhesus PBMCs. 
 
Sample: Monocytes CD4+ CD8+ B Cells 
2646 57.5 0.21 0.067 38.8 
2672 56.9 0.1 0.055 24.9 
2646 Stimulated 48 52.4 16.2 35.7 
2672 Stimulated  59.1 36.7 10 28.8 
 
 
The expression of OX40 on Monocytes and B cells was similar on both infected 
monkeys; however, T cells showed a highly dissimilar pattern of expression for both 
samples. As shown in Figure 9, for both CD8+ and CD4+ T cells, OX40 expression was 
significantly higher on stimulated specimen 2646 in comparison with stimulated specimen 






Figure 9. OX40 Expression in T cells: This figure shows the level of OX40 expression on CD8+ T Cells 
(GREEN) and CD4+ T Cells (RED). 
 
 
BCL-2 and OX40 Co-expressed Upon infected SIV animals  
 
 For characterizing the relationship between BCL-2 and OX40 on Rhesus PBMCs, 
the flow cytometry staining protocol was used to simultaneously identify both proteins on 
the same samples. Samples derived from two additional infected animals (IDs 305-10 and 
412-10) were tested. The animals for this study were equally infected using a repeated low-
dose intrarectal challenge with SIVmac251. They were then placed on ART regimen and 
subsequently deployed of ART treatment in order to evaluate disease progression. Both 
animals developed a high viremia after ART cessation; hence, they are defined as non-
controllers. The degree of expression of BCL-2 and OX40 was assessed with respect to 
the highlighted subpopulations. As shown in Figure 10, the experiment was able to identify 
these two proteins on previously stated subpopulations of Monocytes, B Cells, and T Cells. 




Figure 10. Flow Cytometry Data of specific Rhesus Macaque PBMCs subpopulations – Expression of 
BCL-2 and OX40. Flow cytometry data representing BCL-2 and OX40 expression in subpopulations: 
Monocytes (CD14), B cells (CD20), and T cells (CD3). Data was extracted from samples 305-10 and 412-
10. Double positive data is represented in quadrant II and double negative data is represented in quadrant IV.  
 
 As seen in Figure 9, BCL-2 expression on T cells (both CD4+ and CD8+) appeared 
to be decreased in comparison with what was observed earlier in naïve and controller 
monkeys (Figure 6 and 7). In addition, OX40 expression also decreased in comparison to 
previous data (Figure 9). For all subpopulations, areas of great BCl-2 expression were in 
conjunction with great OX40 expression. The most co-expression was shown in the 
Monocyte subpopulations. For CD4+ T cells, more than 80% of cells positive for OX40 
were also positive for BCL-2. Similarly, for CD8+T cells, 77% positive for OX40 were 
also positive for BCL-2. Overall, these results showed that BCL-2 and OX40 are highly 




BCL-2, OX40, and p27 Expression – T Cells, B Cells, Monocytes, from Rhesus 
Macaque monkeys PBMCs 
 
 Expression of p27 was identified using flow cytometry on Rhesus monkey PBMCs 
in conjunction with BCL-2 and OX40. The subpopulation of T cells was of interest, given 
the shared common expression of all three proteins. CD3 and CD4 markers were needed 
to identify and analyze the data. As depicted in Figure 11A, p27 proteins were highlighted 
in concurrence with both OX40 and BCL-2 proteins. The red dots in the figure represent 
infected cells expressing p27, which are also highlighted with increased OX40 and BCL-2 
expression. These data suggest a relationship between all three of these cell-cycle critical 
proteins. No consistent enrichment of p27+ cells on OX40 population was observed. With 
this knowledge, it cannot be concluded that OX40 is particularly expressed on SIV infected 
cells.  However, infected cells were highly expressing BCL-2; almost 80% of cells 
expressing p27 also expressed BCL-2. Moreover, p27 positive cells had significantly 
higher BCL-2 mean fluorescence intensity (MFI) than p27 negative cells (Figure 11B). 
These results suggest that the number of BCL-2 molecules is higher on infected cells than 




Figure 11. BCL-2 and OX40 Co-expression in Rhesus PBMCs with p27 Expression. This figure 
represents extracted flow cytometry data used to analyze purified PBMCs from Rhesus Macaque monkeys. 
CD3 T cell markers were used in this analysis. (A) Shows the level of co-expression of BCL-2 and OX40 in 
gray dots on infected specimen 412 and 305. (B) P27 expression is shown with red dots representing cells 
expressing the protein. T cells (CD3+) are shown with gray dots. Figures were created using data from 
samples 412-10 and 305-10, SIV infected.  
 
 In order to characterize BCL-2 expression in infected cells, an in vitro SIV infection 
of purified naïve rhesus CD4+ cells was performed. As observed in Figure 12A, p27+ cells 
(in red) were preferentially accumulated on the BCL-2 positive population. On SIV 
primary infected CD4+ cells, more than 90% of the infected cells were highly expressing 
BCL-2. Furthermore, on p27 positive population, MFI levels were significantly higher in 
comparison to p27 negative population. These results suggest an important role of BCL-2 



















Figure 12. BCL-2 Expression with p27 Marker Overlay in Rhesus Macaque PBMCs. (A) This figure 
represents measured BCL-2 expression on CD4+ infected immune cells with (B) an added p27 marker. BCL-
2 expression is shown with gray dots; p27 expression is shown with red dots. Figures were created using data 








Proposed solutions for eliminating HIV have not been successfully determined 
and have led, instead, to the extended stabilization of the virus’ latent phase in CD4+ T 
cells. Current research has explored techniques that involve exterminating the virus by, 
specifically, targeting this latent population, but many of these strategies have been 
inconclusive. The purpose of this analysis was to understand the role that BCL-2 and 
OX40 play in regard to the persistence of HIV in CD4+ T cells.  
 
BCl-2 Expression on Rhesus Macaque PBMCs 
 
The isolation of PBMCs was important, given their known sensitivity to infection, 
especially in the case of HIV/SIV. The expression of BCL-2 on PBMCs was of utmost 
concern because of their suspected link to the preservation of the latent HIV infection. 
Through the experiments with staining and measuring for BCL-2 levels, many 
subpopulations became of interest. White blood cells, known for fighting infections in 
various ways, were affected inversely in regards to infected and naïve specimens. In 
known SIV infected primates, it was important to recognize and highlight the diminished 
levels of BCL-2 on CD8+ T Cells, the cells that are most important in fighting a virus. In 
specifics, comparing primates T631 and 2646 (Figure 5; Table 5), the BCL-2 levels 
were significantly opposite. This can be attributed to primate T631 being uninfected and 
primate 2646 being SIV+ for a prolonged amount of time. Under normal circumstances, 
BCL-2 levels should be high in order to strengthen cell survival. On the other hand, once 
compromised, BCL-2 levels drop, leaving important cells, such as CD8+ T Cells, 
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susceptible to cell death by apoptosis as seen in Figure 5 and Table 1. Low levels of 
CD8+ T cells consequently leave the host vulnerable to infection and eventually death. It 
was important to analyze and investigate whether the upstream protein, OX40, behaved 
in similar ways, in regards to expression during HIV infection.  
 
OX40 Co-Expression on Rhesus Macaque PBMCs 
 
Investigating the levels of OX40 on SIV+ specimen was of concern because of its 
upstream relation with BCL-2. As suspected and proven in Figure 7, staining and 
analyzing for BCL-2 and OX40 were successful. High levels of BCl-2 expression 
correlated with its upstream protein, OX40. This was an important relationship to define 
and analyze, because it ensures any evidence gathered from BCL-2 expression is viable. 
Again, it was important to take note of the diminished level of expression of both proteins 
on CD8 T cells. When these immune cells have low levels of anti-apoptotic proteins, it 
leaves them incredibly susceptible to infection and viral-induced apoptosis. By having 
double assurance for the detection of latent HIV cells, researchers and healthcare 
providers would have the ability to assess with more certainty and accuracy.  
 
BCL-2, OX40, and p27 Expression on Rhesus Macaque PBMCs 
   
 The last expression level measured was p27, one of the more widely known 
proteins in the cell cycle. Previously published research showed that there was a 
connection between HIV-infected cells and heightened levels of p27 expression40. The 
immune response of p27 to HIV is to halt cell replication once infected. With this 
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knowledge, it was imperative to exemplify and reinforce the relationship between OX40 
and BCL-2, in regard to HIV-infected cells. As seen in figures 8 and 9, p27 had a strong, 
positive correlation to both of those anti-apoptotic proteins. This distinct connection 
signifies a possible means of identifying HIV latent CD4+ T cells by any of these 
proteins. With this knowledge and further research, it would be possible to utilize these 
newly defined HIV latent markers as aids for extermination. Further investigation and 
trials will provide patients living with this disease a better quality of life, given that this 
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